The drug development “valley of death” stalls many promising discoveries. Discover how strategic funding and nonprofit support play a crucial role in bridging the gap and driving innovative therapies closer to reality. rainwatercharitablefoundation.org/targeted-fundi…

We’re excited to welcome the global tau community to London for #Tau2025! We look forward to recognizing our 2025 #RainwaterPrize winners and announcing our 2026 #TauopathyChallengeWorkshop theme. Explore what we’re looking forward to: bit.ly/42DcnHG

We were proud to recognize our 2025 #RainwaterPrize winners, Dr. Kaj Blennow and Dr. Bess Frost, at #Tau2025. Thank you to everyone who helped celebrate their groundbreaking contributions to tauopathy research. Explore the impact of the prize.

After celebrating our 2025 #RainwaterPrize recipients at #Tau2025, we are excited to announce that the 2026 Rainwater Prize nominations are now open! To learn more about the prize and submit a nomination, visit: bit.ly/3EOOZyT

This #PSPAwarenessMonth, we remember our founder Richard Rainwater, who was driven by his experience with #PSP to expand his philanthropic efforts to include research into primary tauopathies. Explore his story: bit.ly/42F57w8

Our 2026 #TauopathyChallengeWorkshop will explore advanced biophysical and bioanalytical approaches to probe the structural and thermodynamic properties of tau protein. Learn more about the workshop and sign up for email updates: bit.ly/3EXDyVP

Nominations are now being accepted for the 2026 #RainwaterPrize following the celebration of our 2025 winners, Dr. Kaj Blennow and Dr. Bess Frost, among the international tau community at #Tau2025.To submit a 2026 prize nomination, visit: bit.ly/3Fc9TIu

As a trailblazer in the tauopathy field, Susanne Wegmann was recognized with the 2023 #RainwaterPrize for Innovative Early-Career Scientist. To submit a nomination for 2026, visit: bit.ly/3Fr2zc2

From blood-based biomarkers to PET tracers and new therapeutic approaches, we share our top insights from the extensive discussions at AD/PD 2025. Read our conference report: bit.ly/4k6hojl

The deadline for our 2026 #RainwaterPrize nominations is just one week away! The prize recognizes researchers who have made significant contributions to our understanding of tau-related diseases. Explore more and submit a nomination: bit.ly/44UasRP

For former Congresswoman Jennifer Wexton, establishing May as #PSPAwarenessMonth was driven by her personal #PSP diagnosis. Read about Wexton’s journey in @Washingtonian: washingtonian.com/2024/12/31/rep…

From early-stage target discovery and validation through clinical trials, our #TauConsortium works to bridge the gap known as the “valley of death” by supporting robust translational programs. Learn more: bit.ly/44o7BQc

We are looking forward to announcing the grantees from our 2025 #TauopathyChallengeWorkshop and seeing the applications for our 2026 workshop, which will focus on the structural and thermodynamic properties of tau protein. Sign up for email updates: bit.ly/4l1j7qR

Suppressing “jumping genes” may protect the brain from age-related decline. New research from Rainwater Prize winner Dr. Bess Frost shows that blocking retrotransposons can reduce DNA damage & neurodegeneration, offering a potential path to new therapies. science.org/content/articl…

Letter of interest submissions are now open for the 2026 Tauopathy Challenge Workshop. The focus: exploring the structural and thermodynamic properties of tau and its interactions with other pathologies. Apply by Sept 2: bit.ly/3TJabdE

On #WorldBrainDay, we recognize tau’s impact on neurodegenerative diseases like PSP and FTD. The Rainwater Charitable Foundation supports research to unravel tau’s complexities and advance new diagnostics and therapies. Learn more: rainwatercharitablefoundation.org/medical-resear…

Clinical trials for tauopathies are no longer one size fits all. Researchers are now adopting smarter trial designs that better reflect the complexity of these diseases. Explore three innovative approaches in our latest blog: bit.ly/4o3erm1

A surge of early-stage innovation is driving new momentum in the search for tau-targeted therapies. A review from Dr. Glenn Harris shows two-thirds of the pipeline is now preclinical, many exploring RNA-targeting approaches. Learn more ahead of #AAIC2025: alzres.biomedcentral.com/articles/10.11…